Safety Profile, Contraindications and Regulation
The safety profile of electrochemotherapy follows from its local character: because systemic drug doses are low, systemic adverse effects are limited, while the expected local reactions at the treatment site are pronounced. The tables below summarise the pattern reported in the clinical series within the corpus.
Reported Adverse Events
Most local reactions are part of the treatment response and are read as the expected course rather than complications
| Event | Frequency | Mechanism | Management |
|---|---|---|---|
| Muscle contraction during delivery | Expected | Muscle and nerve stimulation by the pulses | Anaesthesia and, where needed, neuromuscular blockade; choice of pulse frequency |
| Pain at the treatment site | Common | Tissue stimulation and post-procedural inflammation | Analgesia plan; pain may persist for days in some patients |
| Erythema, oedema and superficial necrosis | Common / expected | Response of the treated tissue | Wound care; usually heals by epithelialisation within weeks |
| Hyper- or depigmentation | Common | Melanocyte involvement | The cosmetic outcome should be discussed with the patient beforehand |
| Ulceration and delayed healing | Uncommon | Treatment of large volumes or irradiated tissue | Healing may be markedly prolonged in previously irradiated fields |
| Arrhythmia | Uncommon | Pulses coinciding with the vulnerable cardiac period | ECG synchronisation for applications near the heart |
| Bleomycin-related pulmonary toxicity | Rare but serious | Cumulative bleomycin dose | Lifetime cumulative dose tracking; careful assessment in patients with lung disease |
| Hypersensitivity reaction | Rare | Drug-related | History taking and readiness to intervene |
Contraindications and Cautions
| Condition | Nature |
|---|---|
| Known hypersensitivity to the agent used | Absolute |
| For bleomycin: the lifetime cumulative dose limit has been reached | Absolute |
| Severe renal impairment (bleomycin is renally excreted) | Relative, requires dose adjustment |
| Clinically significant pulmonary fibrosis or advanced lung disease | Relative |
| Pregnancy and breastfeeding | Absolute |
| Uncontrolled arrhythmia, or a pacemaker/ICD near the treatment site | Relative, cardiology assessment |
| Active, uncontrolled infection at the treatment site | Relative |
Bleomycin and Cumulative Dose
The most serious dose-dependent toxicity of bleomycin is pulmonary fibrosis, and risk rises with lifetime cumulative dose. Single-session doses in electrochemotherapy are low compared with systemic chemotherapy regimens, but repeated sessions and the patient’s prior bleomycin exposure must be assessed together.
Risk factors include advanced age, renal impairment, pre-existing lung disease, prior thoracic radiotherapy and exposure to high oxygen concentrations. Limiting the oxygen concentration in any future anaesthesia may therefore become relevant in patients who have received bleomycin, and this should be recorded prominently in the patient’s file.
Regulatory Framework
Electrochemotherapy is a defined interventional procedure in many countries, but device and drug approvals are separate processes
| Document | Scope | Nature |
|---|---|---|
| NICE IPG446 (2013, United Kingdom) | Electrochemotherapy for skin metastases and primary skin cancer | Interventional procedure guidance; use under standard clinical governance |
| NICE IPG478 (2014, United Kingdom) | Primary basal cell and squamous cell carcinoma | Interventional procedure guidance |
| ESOPE (2006, updated 2018) | Standard operating procedures for cutaneous tumours | A European multicentre consensus document; a practice standard, not binding regulation |
| National regulations | Vary by country | Device CE/FDA status, off-label drug use and reimbursement conditions must each be assessed separately |
Safety Considerations Specific to IRE-ECT
Irreversible electroporation has a different safety profile from RE-ECT. Because high-voltage pulses cause severe muscle contraction, general anaesthesia with deep neuromuscular blockade is standard. ECG synchronisation is used routinely to keep pulses out of the vulnerable cardiac period.
For deep organ applications, electrodes are placed under imaging guidance, which brings procedure-specific risks along the needle tract such as bleeding, pancreatitis or bile leak. Preservation of vascular and ductal structures is the reason the method is chosen for adjacent tumours, but that preservation is not absolute: reports of thrombosis and stricture exist in the literature.